Cora has so much experience and knowledge in the industry, we are excited that she is part of our team to drive Onyx forward! Since our interview Cora has been promoted to Group Managing Director in Client Services. Congrats Cora!
read more >>
PRIME GLOBAL EVOLVE TO ENSURE FUTURE SUCCESS
Prime Global 27 June, 2018An internal restructure for Prime Global supports future expansion plans for all six agencies around the globe.
read more >>
#IGNITE
Christine McCann 29 November, 2017DAY ONE
Day one of our #ignite training program starts with an introduction form Christine McCann. All our people are brimming with bright ideas. #training #primepeople #learning
read more >>Not so rare
Acheson Kerry 19 July, 2017Meet Tim. Tim is Tom’s little brother. From birth he had some health complications, but quickly recovered. However, like Tom he had trouble with his speech at the age of 2. The explanation? “He’s just like Tom.” Read more about brothers Tim and Tom on our blog and follow the patient journey and lengthy diagnosis for a child living with a rare disease.
read more >>Duchenne muscular dystrophy
Acheson Kerry 31 May, 2017Duchenne muscular dystrophy is a devastating disease that we still don’t fully understand, and currently there is no cure. This article describes current and new treatment therapies as well as the many challenges scientists still face. https://lnkd.in/gYkEcuH
read more >>Cystic fibrosis is a rare disease that causes damage to the respiratory, digestive and reproductive systems. Our recent article presents what is currently known about this disease as well as existing and future therapies. https://lnkd.in/gkMERE4
read more >>Not So Rare
Acheson Kerry 13 April, 2017Tom and Tim finally reach a diagnosis after finding genetic faults known as AGU. The doctor couldn’t tell them much more, so they were sent to a rare disease specialist for further consultations. For Tom and Tim, and their families, it’s been a long process to reach a clear diagnosis. Sadly, like many other rare diseases, there is no therapy or treatment available. Rare diseases affect more than 350 million people worldwide. We need to support people like Tom and Tim to raise awareness of the long and stressful journey through to diagnosis, to understand the reality of living with a rare condition and to support those families affected by a rare disease.
read more >>
Not so Rare
Acheson Kerry 3 April, 2017In our #RareDisease patient journey, Tom and Tim are finally starting genetic testing to try and reach a diagnosis – read more about their journey and stay tuned to find out what happens.
read more >>Not So Rare
Acheson Kerry 22 March, 2017This week we meet Tilly, Tom and Tim’s younger sister. She was born with no complications and breezed through her early years with good health. As she starts to grow though, you can see that Tilly looks different to her brothers. Read more about their journey so far on our blog: https://lnkd.in/dzd4_T8
read more >>Not so rare
Acheson Kerry 15 March, 2017Rare Disease Patients’ Journey: As Tom and Tim grow, more symptoms arise. Tom is struggling to keep up in class and not progressing academically at the same rate as his class mates. It’s also being noticed that Tim is struggling with his hearing. Read more about their journey so far on our blog: https://lnkd.in/dzd4_T8
read more >>Not so rare
Acheson Kerry 10 March, 2017A person living with a rare disease will have a full diagnosis of an average of 4.8 years. We’re following the journey of brothers Tim and Tom, who are at the beginning of their symptoms. Their story, as well as hundreds and thousands like them #NeedToBeHeard.
#NotSoRare
read more >>
Not so rare
Acheson Kerry 6 March, 2017We want to share what it’s like to live with a #RareDisease and show how long it can take for a patient to get diagnosed. Follow our blog:https://lnkd.in/dzd4_T8 to read about Tom and how his symptoms develop over time. Our first post shares his parents’ concern about the initial symptoms in the first two years of his life. #NotSoRare
read more >>
Not so rare
Acheson Kerry 1 March, 2017Did you know – Rare Diseases affect more than 350 million people worldwide? Today we will be supporting #RareDiseaseDay to help spread global awareness #notsoRARE #medcomm
read more >>
Not so rare
Acheson Kerry 1 March, 2017Rare diseases are more common than you think – this #RareDiseaseDay let’s care for rare and help spread awareness #NotSoRare
read more >>
Not so rare
Acheson Kerry 1 March, 2017Let’s help increase understanding of the reality of #rarediseases #notsoRARE
read more >>
Not so rare
Acheson Kerry 1 March, 2017Today is #RareDiseaseDay. Did you know a patient will end up visiting several doctors before getting an accurate diagnosis? Let’s work together to heighten awareness #notsoRARE Engel PA, Bagal S, Broback M, Boice N. Physician and patient perceptions regarding physician training in rare diseases: The need for stronger educational initiatives for physicians. Journal of Rare Disorders, 2013; 1(2): 1-15.
read more >>
Not so rare
Acheson Kerry 1 March, 2017We’re launching a blog to illustrate the time it takes for a child to receive a diagnosis for a #raredisease
read more >>
Not so rare
Acheson Kerry 1 March, 2017Research into #rarediseases can save and change lives. On #RareDiseaseDay let’s have a common cause to help increase awareness. Engel PA, Bagal S, Broback M, Boice N. Physician and patient perceptions regarding physician training in rare diseases: The need for stronger educational initiatives for physicians. Journal of Rare Disorders, 2013; 1(2): 1-15
read more >>Upcoming Rare Disease Blog posts
Acheson Kerry 28 February, 2017In support of #RareDiseaseDay we are launching a series of blog posts to illustrate the length of time it takes for a child living with a rare disease to receive a diagnosis. The process will be reviewed, from the parent’s perspective looking at the initial symptoms and beyond. Follow the link to find out about Tom. https://onyx-notsorare.tumblr.com/ Stay tuned over the next couple of weeks to find out what happens. #notsoRARE Engel PA, Bagal S, Broback M, Boice N. Physician and patient perceptions regarding physician training in rare diseases: The need for stronger educational initiatives for physicians.
Journal of Rare Disorders, 2013; 1(2): 1-15.
read more >>
Onyx and ONLY Oncology in Brussels
Prime Global 12 February, 2017An amazing scientific sight at the #atomium, in Brussels. Onyx and ONLY Oncology take a break from meetings to enjoy the sculpture and blue skies #medcomms.
read more >>
Amazing scientific sight…! The teams from ONYX and Only Oncology take a few moments on a recent business trip to admire the Atomium as it gleams against the bright blue Brussels sky!
Prime Global 6 February, 2017Picture + Amazing scientific sight! Thanks to ONYX and Only Oncology for sharing this fantastic pic taken on a recent business trip.
read more >>Eteplirsen approved in US for Duchenne muscular dystrophy
Prime Global 17 October, 2016The first drug to treat the underlying cause of Duchenne muscular dystrophy, Exondys (eteplirsen) developed by Sarepta Therapeutics, has secured marketing approval from the U.S. Food and Drug Administration. Duchenne muscular dystrophy is a severe type of muscular dystrophy which generally begins around age four in boys and progresses rapidly.
www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm521263.htm
read more >>StrimvelisTM receives European marketing authorisation to treat very rare disease ADA-SCID
Prime Global 17 October, 2016Strimvelis, (autologous CD34+ cells transduced to express ADA) the first ex vivo stem cell gene therapy has been approved to treat patients with ADA-SCID (severe combined immunodeficiency due to adenosine deaminase deficiency). Children born with ADA-SCID do not have a heathy, fully functioning immune system and are unable to successfully combat everyday infections.
www.gsk.com › en-gb › Media › Press releases
read more >>
Following a successful presentation at the Cell Therapy Manufacturing and Gene Therapy Congress in Brussels, Onyx has again had a strong presence at the prestigious World Orphan Drugs Congress in Washington. This emphasises Onyx strong and continuing commitment to the areas of orphan drugs, rare and ultra-rare diseases and regenerative medicine including cell and gene therapies.
read more >>